Blog
Valuable TargetsAdvanced Tech.
Recent blog posts
Hepratide Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
Hepratide Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Hepratide: Phase 3. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Read →
Auriclosene Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
Auriclosene Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Auriclosene: Phase 3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Read →
Sutetinib Maleate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
Sutetinib Maleate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Sutetinib Maleate: Phase 3. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Read →
Sevasemten Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
Sevasemten Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Sevasemten: Phase 3. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Read →
Quabodepistat Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
Quabodepistat Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Quabodepistat: Phase 3. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Read →
Rovatirelin Hydrate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
Rovatirelin Hydrate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Rovatirelin Hydrate: Phase 3. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Read →
Sitmutolimod Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
Sitmutolimod Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Sitmutolimod: Phase 3. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Read →
Manganese butoxyethyl pyridyl porphyrin Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
Manganese butoxyethyl pyridyl porphyrin Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Manganese butoxyethyl pyridyl porphyrin: Phase 3. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Read →
Galinpepimut-S Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
Galinpepimut-S Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Galinpepimut-S: Phase 3. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Read →
Catadegbrutinib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
Catadegbrutinib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Catadegbrutinib: Phase 3. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Read →
Rilparencel Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
Rilparencel Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Rilparencel: Phase 3. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Read →
Osivelotor Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
Osivelotor Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Osivelotor: Phase 3. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Read →